TIAM Rac1 associated GEF 1Genealiases: NEDLDS · TIAM-1
Q-omics provides the consensus-scored TIAM1 profile across patient tissues and cancer cell-line models. TIAM1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TIAM1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TIAM1 RNA expression shows 20,199 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where TIAM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIAM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIAM1 survival associations across molecular data types. TIAM1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIAM1 RNA expression–survival associations across cancer types. High TIAM1 expression shows unfavorable associations in OV and LUSC, but favorable associations in HNSC, KIRC, THCA and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TIAM1 RNA expression.
This table summarizes TIAM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TIAM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIAM1 shows lower tumor expression in COAD, KICH, UCEC and KIRP and higher tumor expression in THCA and BRCA. The COAD box plot shows higher TIAM1 RNA expression in normal versus tumor tissue (log2 FC = −1.266, t-test p < 0.001).
This table shows molecular features associated with TIAM1 in patient tissues and cancer cell lines. In patient samples, TIAM1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIAM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
